GSK 561679A CAS 885220-61-1

Product Description:

Product Name: GSK 561679A CAS NO: 885220-61-1

Synonyms:

3-(4-Metho-xy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine;Verucerfont;

CPD1230;

GSK561679;

Chemical & Physical Properties:

Appearance: Powder

Assay :≥99.0%

Density: 1.29

PKa: 4.78±0.40(Predicted)

Verucerfont (GSK-561,679) is a drug developed by GlaxoSmithKline which acts as a corticotropin releasing hormone receptor 1 (CRF1) antagonist. Corticotropin-releasing factor (CRF), also known as corticotropin-releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors CRF1 and CRF2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress.

Verucerfont blocks the CRH-1 receptor, and so reduces ACTH release following chronic stress. It is under investigation as a potential treatment for alcoholism, as chronic stress is often a factor in both development of alcoholism and relapse in recovering alcoholics. It has shown promising results in animal studies but has not been tested in humans.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.